Fredun Pharmaceuticals Ltd — Important, 25-05-2026: Company Update

Fredun Pharmaceuticals has announced a board meeting where it approved the financial results for the quarter and financial year ended March 31, 2026. The company proposed a final dividend of 70 paise per equity share (face value ₹10). Significant corporate actions include an increase in Authorised Share Capital from ₹10 Cr to ₹50 Cr and a 2:1 bonus share issue, meaning two new shares for every one existing share, both pending shareholder approval. For the financial year, the underlying profit stood at ₹33.20 Cr, rising to ₹38.03 Cr when excluding one-time tax adjustments.